SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001171843-24-001821
Filing Date
2024-04-04
Accepted
2024-04-03 18:07:28
Documents
9
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 6-K f6k_040324.htm 6-K 6198
2 EXHIBIT 99.1 exh_991.htm EX-99.1 635548
3 EXHIBIT 99.2 exh_992.htm EX-99.2 294203
4 EXHIBIT 99.3 exh_993.htm EX-99.3 600357
5 EXHIBIT 99.4 exh_994.htm EX-99.4 12941
6 EXHIBIT 99.5 exh_995.htm EX-99.5 12945
7 GRAPHIC logo_small.jpg GRAPHIC 6393
8 GRAPHIC logo.jpg GRAPHIC 16844
9 GRAPHIC chart.jpg GRAPHIC 12023
  Complete submission text file 0001171843-24-001821.txt   1612206
Mailing Address SUITE 2400 - 745 THURLOW STREET VANCOUVER A1 V6E 0C5
Business Address SUITE 2400 - 745 THURLOW STREET VANCOUVER A1 V6E 0C5 403-607-2621
XORTX Therapeutics Inc. (Filer) CIK: 0001729214 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-40858 | Film No.: 24820582
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)